These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 27720577

  • 1. Early use of chemotherapy in metastatic prostate cancer.
    Markowski MC, Carducci MA.
    Cancer Treat Rev; 2017 Apr; 55():218-224. PubMed ID: 27720577
    [Abstract] [Full Text] [Related]

  • 2. Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.
    Damodaran S, Lang JM, Jarrard DF.
    J Urol; 2019 May; 201(5):876-885. PubMed ID: 30747897
    [Abstract] [Full Text] [Related]

  • 3. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
    Crawford ED, Higano CS, Shore ND, Hussain M, Petrylak DP.
    J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
    [Abstract] [Full Text] [Related]

  • 4. Systemic therapy in men with metastatic castration-resistant prostate cancer: a systematic review.
    Loblaw DA, Walker-Dilks C, Winquist E, Hotte SJ, Genitourinary Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care.
    Clin Oncol (R Coll Radiol); 2013 Jul; 25(7):406-30. PubMed ID: 23587782
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
    Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN.
    Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
    [Abstract] [Full Text] [Related]

  • 6. [Treatment situation in metastastic Castration Naive Prostate Cancer (mCRPC) and the implications on clinical routine].
    Wülfing C, Bögemann M, Goebell PJ, Hammerer P, Machtens S, Pfister D, Schwentner C, Steuber T, von Amsberg G, Schostak M.
    Urologe A; 2019 Sep; 58(9):1066-1072. PubMed ID: 31041460
    [Abstract] [Full Text] [Related]

  • 7. Abiraterone acetate in combination with prednisone in the treatment of prostate cancer: safety and efficacy.
    Manceau C, Mourey L, Pouessel D, Ploussard G.
    Expert Rev Anticancer Ther; 2020 Aug; 20(8):629-638. PubMed ID: 32552120
    [Abstract] [Full Text] [Related]

  • 8. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
    Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y.
    Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of second-line agents for treatment of metastatic castration-resistant prostate cancer progressing after docetaxel. A systematic review and meta-analysis.
    Perletti G, Monti E, Marras E, Cleves A, Magri V, Trinchieri A, Rennie PS.
    Arch Ital Urol Androl; 2015 Jul 07; 87(2):121-9. PubMed ID: 26150028
    [Abstract] [Full Text] [Related]

  • 10. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer.
    Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES.
    Prostate; 2015 Nov 07; 75(15):1814-20. PubMed ID: 26306637
    [Abstract] [Full Text] [Related]

  • 11. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
    Brasso K, Thomsen FB, Schrader AJ, Schmid SC, Lorente D, Retz M, Merseburger AS, von Klot CA, Boegemann M, de Bono J.
    Eur Urol; 2015 Aug 07; 68(2):317-24. PubMed ID: 25108579
    [Abstract] [Full Text] [Related]

  • 12. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.
    Wallis CJD, Klaassen Z, Bhindi B, Goldberg H, Chandrasekar T, Farrell AM, Boorjian SA, Kulkarni GS, Karnes RJ, Satkunasivam R.
    Eur Urol; 2018 Jun 07; 73(6):834-844. PubMed ID: 29037513
    [Abstract] [Full Text] [Related]

  • 13. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Ueda Y, Matsubara N, Takizawa I, Nishiyama T, Tabata K, Satoh T, Kamiya N, Suzuki H, Kawahara T, Uemura H.
    Jpn J Clin Oncol; 2015 Aug 07; 45(8):774-9. PubMed ID: 25981621
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study.
    Kobayashi K, Okuno N, Arai G, Nakatsu H, Maniwa A, Kamiya N, Satoh T, Kikukawa H, Nasu Y, Uemura H, Nakashima T, Mikami K, Iinuma M, Tanabe K, Furukawa J, Kobayashi H.
    Jpn J Clin Oncol; 2021 Apr 01; 51(4):544-551. PubMed ID: 33324967
    [Abstract] [Full Text] [Related]

  • 15. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
    Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, Henry AM, Joniau S, Lam TB, Mason MD, van der Poel HG, van der Kwast TH, Rouvière O, Wiegel T, Mottet N.
    Eur Urol; 2017 Apr 01; 71(4):630-642. PubMed ID: 27591931
    [Abstract] [Full Text] [Related]

  • 16. Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis.
    Tucci M, Bertaglia V, Vignani F, Buttigliero C, Fiori C, Porpiglia F, Scagliotti GV, Di Maio M.
    Eur Urol; 2016 Apr 01; 69(4):563-573. PubMed ID: 26422676
    [Abstract] [Full Text] [Related]

  • 17. Taxane-based Combination Therapies for Metastatic Prostate Cancer.
    Corn PG, Agarwal N, Araujo JC, Sonpavde G.
    Eur Urol Focus; 2019 May 01; 5(3):369-380. PubMed ID: 29275145
    [Abstract] [Full Text] [Related]

  • 18. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    Smith MR, Saad F, Rathkopf DE, Mulders PFA, de Bono JS, Small EJ, Shore ND, Fizazi K, Kheoh T, Li J, De Porre P, Todd MB, Yu MK, Ryan CJ.
    Eur Urol; 2017 Jul 01; 72(1):10-13. PubMed ID: 28314611
    [Abstract] [Full Text] [Related]

  • 19. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
    Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, European Association of Urology.
    Eur Urol; 2014 Feb 01; 65(2):467-79. PubMed ID: 24321502
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.